Home / Business and Economy / Melanoma Drug Shows Promise in Tough Cases
Melanoma Drug Shows Promise in Tough Cases
22 Jun
Summary
- Brenetafusp data showed consistent responses in advanced melanoma patients.
- The drug demonstrated an 87% survival rate in a specific patient group.
- Immunocore is developing novel TCR bispecific immunotherapies.
Updated trial results evaluating brenetafusp for heavily pretreated advanced melanoma patients were presented on May 31 at the 2026 American Society of Clinical Oncology Annual Meeting. The data indicated consistent responses and survival, notably in patients with poor prognosis and primary PD-1 resistance.
Brenetafusp monotherapy demonstrated a 6-month overall survival rate of 87% and a 52% disease control rate in a specific patient subgroup. These findings bolster confidence in brenetafusp's potential, particularly in combination with nivolumab for first-line advanced melanoma.
Immunocore Holdings plc is a biotechnology firm focused on developing ImmTAX, a novel class of TCR bispecific immunotherapies. The company has a pipeline that includes several promising product candidates beyond brenetafusp.
